MDL | MFCD31813721 |
---|---|
Molecular Weight | 336.41 |
Molecular Formula | C19H16N2O2S |
SMILES | COC1=CC=C(C2=CNC3=NC=CC(C4=CSC=C4)=C32)C(OC)=C1 |
SIK2 <1 nM (IC 50 ) |
SIK1 21.63 nM (IC 50 ) |
SIK3 6.63 nM (IC 50 ) |
ARN-3236 inhibits SIK2 activity with an IC
50
<1 nM
[2]
.
ARN-3236 inhibits cell growth and increases NSC 125973 sensitivity in ovarian cancer cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
Cell Line: | HEY and A2780 human ovarian cancer cell lines. |
Concentration: | 0-10 μM. |
Incubation Time: | 24 hours. |
Result: | Inhibited SIK2 activity with an IC 50 <1 nM. |
ARN-3236 (60 mg/kg, orally) sensitizes ovarian cancer to NSC 125973 in vivo [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | SKOv3ip-bearing mice and OVCAR8-bearing mice [2] . |
Dosage: | 60 mg/kg. |
Administration: | Orally once daily for 3 weeks (SKOv3ip-bearing mice) and 4 weeks (OVCAR8-bearing mice). |
Result: | Sensitized ovarian cancer to NSC 125973. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 297.26 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.9726 mL | 14.8628 mL | 29.7256 mL |
5 mM | 0.5945 mL | 2.9726 mL | 5.9451 mL |
10 mM | 0.2973 mL | 1.4863 mL | 2.9726 mL |